One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Arvinas logo
Arvinas ARVN
$ 6.97 1.12%
report update icon

Quarterly report 2026-Q2
added 08-04-2026

Arvinas Financial Ratios 2025-2011 | ARVN

Brief overview of Arvinas's multiples and efficiency

This overview follows the five latest available observations from 2021 through 2025.

The valuation comparison uses P/S 3.31x (median 13.35x), P/B 2x (median 3.1x). Valuation is roughly 55.4% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.

End-period return metrics are ROE -18.7%, ROA -11.3%, ROCE -27.3%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.

The cash cycle accelerated by 49.8 days to 4.7 days. Less capital is tied up in operations.

Conclusion

Arvinas's valuation is lower, but weak quality metrics call for caution. Recovery in earnings and capital returns is the key catalyst.

Annual Financial Ratios Arvinas

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-10.7 -6.3 -7.2 -6.2 -17.0 -25.9 -23.4 -3.9 - - - - - - -

P/S

3.3 4.7 33.7 13.3 60.5 119.4 38.3 11.4 - - - - - - -

EPS

-1.1 -2.8 -6.6 -5.3 -3.8 -3.0 -2.1 -25.4 -15.1 - - - - - -

EV (Enterprise Value)

1.01 B 1.68 B 2.98 B 2.38 B 3.93 B 2.58 B 1.71 B 223 M 35.7 M 13.9 M - - - - -

EBITDA per Share

-1.63 -3.42 -7.15 -4.83 -3.67 -2.98 -1.5 -4.57 - - - - - - -

EV/EBITDA

-8.7 -6.8 -7.5 -9.3 -20.4 -21.2 -33.2 -3.8 - - - - - - -

PEG

31.32 -0.21 -0.27 - - 0.38 -0.26 0.0 - - - - - - -

P/B

2.0 2.2 4.0 3.1 4.1 4.8 7.3 1.2 - - - - - - -

P/CF

-3.2 -4.8 -7.6 -6.4 5.8 -34.5 -35.1 -8.6 - - - - - - -

ROE %

-18.67 -35.43 -55.61 -50.10 -24.43 -18.58 -31.01 -30.35 - - - - - - -

ROA %

-11.28 -18.23 -28.13 -22.30 -12.08 -16.63 -23.30 -20.82 - - - - - - -

ROCE %

-27.31 -44.54 -60.83 -46.59 -24.10 -18.81 -19.17 -24.84 - - - - - - -

Current Ratio

2.5 2.1 2.0 1.8 2.0 9.6 8.9 8.5 - - - - - - -

DSO

4.7 3.9 2.3 22.2 54.5 7.0 53.3 128.2 - - - - - - -

Operating Cycle

4.7 4.0 2.3 22.2 54.5 7.0 - - - - - - - - -

Cash Conversion Cycle

4.7 4.0 2.3 22.2 54.5 7.0 - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Arvinas

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

2.61 -0.9 -0.48 -0.84 1.14 - -0.68 -0.49 -0.97 - -1.18 -1.25 -1.54 - -1.24 -1.32 -1.2 - -0.94 -1.03 -0.84 - -0.79 -0.65 -0.56 -0.56 -0.54 -0.55 -0.46 -0.52 -62.38 -11.96 -39.86 -4.9 -3.37 -3.52 -3.29 - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

2.54 -0.99 -0.59 -0.97 0.99 - -0.82 -0.66 -1.15 - -1.34 -1.37 -1.62 - -1.18 -1.21 -1.06 - -0.93 -1.04 -0.84 - -0.79 -0.67 -0.59 -0.61 0.18 -0.58 -0.5 -0.54 -6.9 -4.4 -2.19 -2.8 -3.25 -3.54 -3.33 - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-1.02 -18.60 -12.10 -11.75 -13.08 -25.64 -39.64 -45.61 -55.77 -44.39 -55.04 -51.48 -45.88 -29.86 -35.58 -33.55 -29.78 -21.01 -25.81 -24.02 -18.78 -12.11 -21.40 -24.40 -28.04 -31.01 -33.50 -35.50 -33.67 -30.36 -10.86 9.38 -3.04 7.72 10.45 - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

5.31 -11.50 -6.82 -5.42 -4.41 -12.69 -18.74 -20.67 -24.88 -19.16 -24.12 -22.33 -19.10 -12.14 -19.94 -14.98 -21.00 -16.74 -21.03 -21.63 -16.86 -10.84 -17.82 -19.38 -21.56 -23.30 -24.40 -25.26 -23.51 -20.82 -19.81 -22.67 -2.08 -7.07 -9.57 - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-6.80 -25.17 -18.97 -19.29 -21.22 -32.03 -48.20 -54.00 -63.08 -49.42 -59.76 -53.41 -45.30 -28.14 -33.92 -32.47 -29.44 -21.46 -26.41 -24.74 -19.49 -12.71 -22.77 -15.40 -19.40 -22.73 -25.08 -37.80 -35.90 -32.06 -10.99 9.77 -3.13 8.67 10.47 - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

6.0 2.5 3.0 3.0 2.9 2.1 2.0 1.9 2.0 2.0 1.8 1.8 1.8 1.8 1.9 - 1.9 2.0 2.0 10.5 10.3 9.5 9.6 9.6 9.6 4.0 4.0 4.0 4.0 3.2 3.2 3.2 3.2 1.0 1.0 - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

9.5 64.6 22.6 1.8 1.5 - 4.0 1.1 - - 20.8 0.1 1.4 - 3.3 1.9 25.8 - 9.3 - - - 12.0 15.9 7.3 0.6 0.1 - 31.5 73.6 75.0 74.5 308.4 886.9 683.5 - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - 22.6 1.8 1.5 - 4.0 - - - 20.8 - - - 3.3 1.9 25.8 - 9.3 - - - 12.0 15.9 7.3 0.6 0.1 - 31.5 73.6 75.0 74.5 308.4 886.9 683.5 - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

- - 22.6 1.8 1.5 - 4.0 - - - 20.8 - - - 3.3 1.9 25.8 - 9.3 - - - 12.0 15.9 7.3 0.6 0.1 - 31.5 73.6 75.0 74.5 308.4 886.9 683.5 - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Arvinas, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Aptorum Group Limited Aptorum Group Limited
APM
- - $ 5.72 M chinaChina
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
BioAtla BioAtla
BCAB
$ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
- - $ 3.85 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
ADiTx Therapeutics ADiTx Therapeutics
ADTX
- - $ 374 usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
- - $ 5.18 B usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bio-Path Holdings Bio-Path Holdings
BPTH
- - $ 100 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Diffusion Pharmaceuticals Diffusion Pharmaceuticals
DFFN
- 11.68 % $ 8.97 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
- -5.68 % $ 8.28 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
- - $ 661 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
- 7.55 % $ 38.1 M usaUSA
Eyenovia Eyenovia
EYEN
- 49.81 % $ 13.2 M usaUSA
FibroGen FibroGen
FGEN
- - $ 889 M usaUSA
Homology Medicines Homology Medicines
FIXX
- 0.77 % $ 53.4 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
- - $ 4.47 B usaUSA
Frequency Therapeutics Frequency Therapeutics
FREQ
- - $ 528 M usaUSA
Galecto Galecto
GLTO
- - $ 762 M danmarkDanmark
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Graybug Vision Graybug Vision
GRAY
- -11.23 % $ 9.65 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
Hoth Therapeutics Hoth Therapeutics
HOTH
- - $ 18.8 M usaUSA
IMARA IMARA
IMRA
- 15.96 % $ 663 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
- - $ 1.45 B britainBritain
KemPharm KemPharm
KMPH
- -0.34 % $ 200 M usaUSA
Kezar Life Sciences Kezar Life Sciences
KZR
- - $ 53.3 M usaUSA
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
- - $ 63.4 M usaUSA
Magenta Therapeutics Magenta Therapeutics
MGTA
- -7.74 % $ 41.6 M usaUSA
NovaBay Pharmaceuticals NovaBay Pharmaceuticals
NBY
- - $ 11.3 M usaUSA